SPECTRE (Eurostars)- PTA procedures in MRI
SPECTRE is a new project within the Eurostars program and is a collaboration between Fraunhofer Mevis (Bremen, DE), Radboud University Medical Centre (Nijmegen, NL) and Soteria Medical BV (Arnhem, NL) . The project enables Nano4Imaging to construct and test robot-controlled PTA catheters for use in MRI procedures. Project start was on January 1st 2018.
IMAGINE (BMBF)- Markers and instruments for MPI
IMAGINE is the project Acronym for a project within the German-Turkish collaboration between BMBF and TUBITAK (2+ 2 project). IMAGINE will allow Nano4Imaging to extend its MagnaFy technology to Magnetic Particle Imaging (MPI). The project is a collaboration with German partner UKSH (University Hospital in Lubeck) and two Turkish Partners, Aselsan and Bilkent University. The project has officially started on October 1st 2017.
Open Mind (Horizon 2020)- customized production of medical devices
OpenMind, is a Horizon 2020 project lead by Fraunhofer IPT (Aachen), involving a total of 9 partners, including 6 SMEs to further develop and extend the production system for medical devices. The official program kick-off was on April 27th 2016 in Brussels. The project enables Nano4Imaging as end-user in the consortium, to further optimize the current production process for current and new MRI compatible instruments. Partners are Fraunhofer IPT (coordinator), Diribet, Blue Acre Technology, Tamponcolor, Gimac, ICS and Fond Politechnica Milano. The OPENMIND_brandbook can be downloaded here. The latest two newsletters can de downloaded from NewsletterN2 and Newsletter-N3.
Marie-Curie training network (iTERM)– contrast agents for MRI- completed
The overarching scientific objective of iTERM was the development of new materials and implants for the bio-engineering of soft tissue (skin, urogenital) and hard (bone) tissue as well as state-of-the-art novel multimodality visualisation procedures to monitor the implants. In collaboration with the research group on Experimental and Molecular Imaging (prof. Fabian Kiessling) at the Technical University of Aachen (RWTH) new MRI contrast agents, based on hemin derivatives were developed and a European patent was obtained (EP 3295 962 ).